Trial Profile
A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics After Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients With Moderate and Severe Traumatic Brain Injury.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs SLV 334 (Primary)
- Indications Traumatic brain injuries
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Abbott Laboratories
- 01 Apr 2022 This trial has been completed in France (End Date: 16 Aug 2010) according to European Clinical Trials Database record.
- 04 Jul 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2008-001409-40).
- 25 Aug 2011 Additional lead trial investigator (Juliana Bronzowa) identified as reported by ClinicalTrials.gov.